High-throughput pharmacokinetics: Cassette dosing

Current Opinion in Drug Discovery and Development

Volumn 2, Issue 1, 1999, Pages 20-25

  Bayliss, Martin K ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; RECEPTOR;

AUTOMATION; COST; DRUG INDUSTRY; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MODEL; PHARMACOKINETICS; REVIEW;

EID: 0032900659     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Beeley U, Duckworth DM: The impact of genomics on drug design. Drug Discovery Today (1996) 1:474-480.
2. Gordon EM, Gallop MA, Patel DV: Strategy and tactics in combinatorial organic synthesis. Applications to drug discovery. Ace Chem Res (1996) 29:144-154.
3. Berman J, Howard RJ: Combinatorial drug discovery: Concepts. In: Combinatorial Chemistry and Molecular Diversity in Drug Discovery. Gordon E, Kerwin J (Eds). John Wiley & Sons Inc, London (1998).
4. A good review of the challenges presented by the combinatorial approach to drug discovery.
5. Haliday RG, Drasdo AL, Lumley CE, Walker SR: The allocation of resources for R & D in the world's leading pharmaceutical companies. Res Develop Management (1997)27:63-77.
6. Vagelos PR: Are prescription drug prices too high? Science (1991)252:1080-1084.
7. Glaxo Wellcome sets targets for research improvement Scrip (1997) 2294:8.
8. Prentis RA, Lis Y, Walker SR: Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (19641985). Br J Clin Pharmacol(1988) 25:387-396.
9. Rodrigues AD: Preclinical drug metabolism in the age of high-throughput screening: An industrial perspective. Pharm Res (1997) 14:1504-1510.
10. Details the challenges facing the traditional' preclinical activities involved in drug discovery and development in meeting the demands of the high-throuhput era as seen by Merck.
11. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev (1997) 23:3-25.
12. Details the first computational approach to modeling absorption.
13. Navia MA, Chaturvedi PR: Design principles for orally bioavailable drugs. Drug Discovery Today (1996) 1:179-189.
14. Tarbit MH, Berman J: High-throughput approaches for evaluating absorption, distribution, metabolism and excretion properties of lead compounds. Curr Opin Chem Biol (1998) 2:411-416.
15. A detailed review of the approach taken by Glaxo Wellcome and the progress made in adapting the traditional preclinical activities to high-throughput drug discovery.
16. Adkison KK, Halm K, Lee FW. Tonq WQ. Berman J, Shaffer JE: Multiple in one dosing: Increasing compound throughput in whole animal pharmacokinetics. Pharm Res (1996)13:5486.
17. Berman J, Halm K, Adkison KK, Shaffer JE: Simultaneous pharmacokinetic screening of a mixture of compounds in the dog using API LC/MS/MS analysis for increased throughput. J Med Chem (1997) 40:827-829.
18. This paper was the first to report the development of the approach of administering mixtures of compounds to a single animal and then using the analytical capability of mass spectrometry to analyse the mixtures. This approach has significantly increased the throughput of in vivo studies during the lead optimization stage of drug discovery. Furthermore, this has had an impact on the ethical considerations, reducing the numbers of animals used.
19. Adkison KK, Halm KA, Shaffer JE, Drewry D, Sinhababu AK, Berman J: Discovery of a potent and selective a-1A antagonist: Utilization of a rapid screening method to obtain pharmacokinetic parameters. In: Integration of Pharmaceutical Discovery and Development: Case Studies. Borchardt R, Freidinger RM, Sawyer TK, Smith PL (Eds). Plenum Press, New York (1998) 18.
20. Ohlah TV, McLoughlin DA, Gilbert JD: The simultaneous determination of mixtures of drug candidates by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry as an in vivo drug screening procedure. RapidCommMassSpectrom( 1997) 11:17-23.
21. The authors detail the successful use of administering mixtures of compounds via the oral route. This is one of the few full papers on cassette dosing.
22. McLoughlin DA, Ohlah TV, Gilbert JD: A direct technique for the simultaneous determination of 10 drug candidates in plasma by liquid chromatography-atmospheric pressure chemical ionization mass spectrometery interfaced to a Prospekt solid-phase extraction system. J Pharm Biomed /4na/(1997) 15:1893-1901.
23. Dobson RLM, Quijano M, Coombs MA, Neubecker TA, Dowty ME, Dietsch CR: Bioavailability estimates for multiple polar compounds: N-in-One dosing and HPLC/MS/MS analysis of rat urine. 45 Annual Conference of the American Society for Mass Spectrometry, Palm Springs, CA, USA (1997). Conference proceedings, 703.
24. These researchers from Procter and Gamble used urinary recovery to assess oral bioavailability in compounds grouped into a cassette of six at two different dose levels. Correlations between discrete and cassette data were good.
25. Bullen W, Rayes R, Hunt K, Tran M, Welty D: Development and validation of high-throughput LC/MS/MS pharmacokinetic screens - Cassette dosing. 45 Annual Conference of the American Society for Mass Spectrometry, Palm Springs, CA, USA (1997). Conference proceedings, 725.
26. This abstract describes work at Parke-Davis that used cassette dosing to improve the selection of compounds for in vivo efficacy testing. Both clearance and half-life were correlated with date after investigating compounds as discretes.
27. th Annual Conference of the American Society for Mass Spectrometry, Palm Springs, CA, USA (1997). Conference proceedings, 1300.
28. Baker TR, Wolf FE, Cruze CA, Bomes DM, Peng SX, Patel VS: Comparing preclinical pharmacokinetic data obained from conventional, population, SIL- coadministration and N-inOne studies. 45 Annual Conference of the American Society for Mass Spectrometry, Palm Springs, CA, USA (1997). Conference proceedings, 726.
29. Korfmacher WA, Bryant MS, Veals J, Cox KA, Ng K, Un CC: Strategies for high-throughput assays using HPLCatmospheric pressure ionization-MS/MS in new drug discovery applications. 45 Annual Conference of the American Society for Mass Spectrometry, Palm Springs, CA, USA (1997). Conference proceedings, 698.
30. Potts W, Lundberg D, Peters J, Bi H, Stelman G, Sandhu P: Pharmacokinetic assessment of a mixture of compounds in the rat using simultaneous dosing and simultaneous LC/MS/MS quantitation. ISSX Proceedings (1995) 8:404.
31. Liang L, Chi C, Shen H, Zeng H, Huang SM, Chien B: N-inOne approach for rapid pharmacokinetic study of receptor antagonists using LC/MS/MS. 45 Annual Conference of the American Society for Mass Spectrometry, Palm Springs, CA, USA (1997). Conference proceedings, 711.
32. Hallak H, Kindt E, Hayes R, Bocan T: Oral pharmacokinetic profiling of matrix metalloproteinase inhibitors using mixtures of drug candidates and LC/MS/MS analysis. Pharm Res (1997) 14:S359.
33. Beaudry F, Le Blanc JCY, Coutu M, Brown NK: In vivo pharmacokinetic screening in cassette dosing experiments: the use of on-line Prospekt® liquid chromatography/atmospheric pressure chemical ionization tandem mass Spectrometry technology in drug discovery. Rapid Comm Mass Spectrom (1998) 12:1216-1222.
34. These researchers at Phoenix International Life Sciences (Canada) were a beta-test site for the Sciex AP13000® mass spectrometer. They describe the construction of calibration curves of 64 test compounds (one internal reference and 63 others) grouped into a single cassette.
35. Frick LW, Adkison KK, Wells-Knecht KJ, Woollard P, Higton DM: Cassette dosing: rapid in vivo assessment of pharmacokinetics. Pharmaceutical Science and Technology 7bday(1998) 1:12-18.
36. This review details the experience within Glaxo Wellcome of administering mixtures of compounds to single animals and the problems associated with cassette size.
37. Toon S, Rowland M: Structure-pharmacokinetic relationships among the barbiturates in the rat. J PharmacolExp The/-(1983) 225:752-763.
38. Korfmacher WA, Cox KA, Bryant MS, Veals J, Ng K, Watkins R, Lin CC: HPLC-API/MS/MS: a powerful tool for integrating drug metabolism into the drug discovery process. Drug Discovery Today (1997) 2:532-537.
39. A comprehensive review of the versatility provided by mass Spectrometry during the drug discovery process. Highlights the potential efficiency gains provided by the widespread use of this sensitive and selective technique.